Prognostic Value of Platelet Count in Diffuse Large B-Cell Lymphoma

Chen, Ling-Ping; Lin, Szu‐Ting; Yu, Ming-Sun

doi:10.1016/j.clml.2011.09.215

Cited by 33 publications

(51 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike follicular lymphoma, in which Hb < 12.0 g ⁄ dL was known to be prognostic, (7,8) the current study showed that no difference of EFS between patients with G0 and G1 anemia and only G ≥ 2 anemia showed an association with inferior EFS. In a previous Taiwanese study evaluating 100 patients with DLBCL treated with rituximab-containing immunochemotherapy, Hb < 12.0 g ⁄ dL did not show a significant association with inferior progression-free survival or OS, (13) consistent with our result. It is not certain whether milddegree G1 anemia does not have any impact on outcomes at all or might have shown a significant relation to poor survival if it were analyzed in a larger patient population.…”

Section: Discussionsupporting

confidence: 92%

Anemia as a useful biomarker in patients with diffuse large B‐cell lymphoma treated with R‐CHOP immunochemotherapy

et al. 2014

View full text Add to dashboard Cite

The aim of the current study is to evaluate the prognostic value of anemia, an easily estimable parameter in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) immunochemotherapy. A total of 157 patients with newly diagnosed diffuse large B-cell lymphoma treated with ≥1 cycle of R-CHOP were included. Hemoglobin level without red cell transfusion within 7 days of initiation of treatment was chosen as a parameter of baseline cancer-induced anemia. To investigate the clinical significance of chemotherapy-induced anemia and its recovery after completion of treatment, 87 patients in complete remission for ≥6 months from the time of the last cycle of R-CHOP were grouped and analyzed separately. Patients with a cancer-induced anemia of hemoglobin <10 g/dL showed inferior event-free and disease-free survival compared to those with hemoglobin ≥10 g/dL. This finding was observed irrespective of the status of pre-treatment bone marrow involvement. In multivariate analysis, hemoglobin <10 g/dL was found to be an international prognostic index-independent prognostic factor. Risk of relapse was significantly higher for patients who were still anemic at 6 months after R-CHOP, compared to those who achieved complete recovery from chemotherapy-induced anemia within 6 months.

show abstract

Section: Discussionsupporting

confidence: 92%

Anemia as a useful biomarker in patients with diffuse large B‐cell lymphoma treated with R‐CHOP immunochemotherapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In human large B‐cell lymphomas, the low platelet count is correlated to a higher BM involvement and is an independent poor prognostic factor . Our results and those by Graff et al .…”

Section: Discussionsupporting

confidence: 82%

Peripheral blood abnormalities and bone marrow infiltration in canine large B‐cell lymphoma: is there a link?

Martini

Melzi

Comazzi

et al. 2013

Vet Comparative Oncology

View full text Add to dashboard Cite

Official guidelines do not consider bone marrow (BM) assessment mandatory in staging canine lymphoma unless blood cytopenias are present. The aim of this study was to find out if blood abnormalities can predict marrow involvement in canine large B-cell lymphoma. BM infiltration was assessed via flow cytometry. No difference was found between dogs without haematological abnormalities and dogs with at least one. However, the degree of infiltration was significantly higher in dogs with thrombocytopenia, leucocytosis or lymphocytosis and was negatively correlated to platelet count and positively to blood infiltration. Our results suggest that blood abnormalities are not always predictive of marrow involvement, even if thrombocytopenia, leucocytosis or lymphocytosis could suggest a higher infiltration. BM evaluation should therefore be included in routine staging in order not to miss infiltrated samples and to improve classification. However, its clinical relevance and prognostic value are still not defined and further studies are needed.

show abstract

“…Although the association between a low platelet count and poor prognosis is presumed to be caused by the BM involvement of PTCL to some extent, thrombocytopenia was a significant risk factor for poor survival even after adjusting for BM involvement by multivariate analyses in our study, with an HR of 2.19 (95% CI 1.25–3.82; p = 0.006) for the PFS, and 2.94 (95% CI 1.47–5.86; p = 0.002) for the OS. This could indicate an adverse immune response of the host, intolerance to subsequent chemotherapy, and vulnerability to complications, as proposed by Chen et al [22] to explain the correlation between the platelet count at diagnosis and survival outcomes in patients with DLBL, but the precise mechanism involved is yet to be elucidated.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Platelet Count in Patients with Peripheral T Cell Lymphoma

et al. 2019

View full text Add to dashboard Cite

Background: Peripheral T cell lymphoma (PTCL) is a heterogeneous entity with poor survival. We evaluated the neutrophil-to-lymphocyte ratio (NLR), absolute lymphocyte count (ALC), and platelet count as new prognostic factors for PTCL. Patients and Methods: We retrospectively analyzed 77 patients with PTCL initially treated with anthracycline-based chemotherapy. Survival curves were compared between groups with different initial NLR (iNLR), end-point NLR (eNLR), initial ALC, and platelet counts. Cox regression was used to analyze the risk factor for survival. Results: Patients with a higher eNLR (≥3), lymphopenia (< 1,000/μL), and thrombocytopenia (< 150 K/μL) had an inferior progression-free survival (PFS) and overall survival (OS) compared to their counterparts, while a higher iNLR (≥3) was predictive of a shorter OS but not PFS. Among these, thrombocytopenia was an independent poor prognostic factor for both PFS and OS, with a hazard ratio of 2.42 (p = 0.012) for PFS and 4.21 (p = 0.006) for OS. The presence of thrombocytopenia further stratified patients with a worse prognosis within overlapping risk-groups by the prognostic index for PTCL. Conclusions: Our study showed that thrombocytopenia at diagnosis was an independent prognostic factor for survival in patients with PTCL.

show abstract

Prognostic Value of Platelet Count in Diffuse Large B-Cell Lymphoma

Cited by 33 publications

References 30 publications

Anemia as a useful biomarker in patients with diffuse large B‐cell lymphoma treated with R‐CHOP immunochemotherapy

Anemia as a useful biomarker in patients with diffuse large B‐cell lymphoma treated with R‐CHOP immunochemotherapy

Peripheral blood abnormalities and bone marrow infiltration in canine large B‐cell lymphoma: is there a link?

Prognostic Value of Platelet Count in Patients with Peripheral T Cell Lymphoma

Contact Info

Product

Resources

About